Baltzan M A, Ahmed S, Baltzan R B, Marshall R P, Thoma E L, Nicol M F
Baltzan Clinic, Saskatoon, Canada.
Clin Nephrol. 1997 Jun;47(6):351-5.
Examination of nephrology practice variations in living donor renal grafts to determine their influence on organ supply, quality, and cost of chronic renal failure therapy.
Saskatchewan chronic dialysis, cadaveric, and living donor renal grafts in 1983-1994 inclusive.
Saskatchewan has three dialysis (I, II, III) and one transplant clinic. In the period the renal graft incidences/million population by these dialysis clinics by organ source were; Cadaveric: 23.1, 23.2, 21.1 (p = ns). Living: 5.4, 21.7, 8.3 (I or III vs II p < 0.000, I vs III p < 0.061). Total: 28.7, 44.7, 29.4. Living donor series A is 79 grafts in patients under age 60 with primary renal disease. Series B is 20 grafts in patients with secondary renal disease or over age 59. Series A ten-year actuarial patient survival is 92% and B 44%. Series A ten-year actuarial graft survival (including regrafts) is 77% and B 39%. Rehabilitation rate in patients with functioning grafts is 88.5%. Province-wide extension of the Clinic II living-donor graft rate in 1983-1994 would have produced 160 more renal grafts or 59% of those receiving chronic dialysis in 1994. The annual maintenance for a graft with the initial grafting cost taken over five years was $10,825 and the dialysis cost $40,100.
(1) nephrology practice variations caused a 2.5-4.0-fold difference in living donor renal graft rates, indicating patient education by the attending nephrologist influences the living donor transplantation rate, (2) with such education the combined living donor and the cadaveric organ supply virtually meets graft demand, (3) living donor renal grafts yield a better quantity and quality of life and better cost control than dialysis with their annual cost being one-quarter that for dialysis.
研究活体供肾肾移植中肾脏病治疗实践的差异,以确定其对器官供应、质量及慢性肾衰竭治疗费用的影响。
1983年至1994年(含)期间萨斯喀彻温省的慢性透析、尸体供肾及活体供肾肾移植情况。
萨斯喀彻温省有三家透析诊所(I、II、III)和一家移植诊所。在此期间,这些透析诊所按器官来源统计的每百万人口肾移植发生率为:尸体供肾:23.1、23.2、21.1(p=无显著性差异)。活体供肾:5.4、21.7、8.3(I或III与II相比p<0.000,I与III相比p<0.061)。总计:28.7、44.7、29.4。活体供肾系列A为60岁以下原发性肾病患者的79例移植。系列B为继发性肾病患者或59岁以上患者的20例移植。系列A的10年精算患者生存率为92%,系列B为44%。系列A的10年精算移植生存率(包括再次移植)为77%,系列B为39%。有功能移植的患者康复率为88.5%。1983年至1994年期间若将诊所II的活体供肾移植率推广至全省范围,将会多产生160例肾移植,即1994年接受慢性透析患者的59%。将初始移植费用分摊到五年的情况下,一个移植肾的年度维护费用为10,825美元,透析费用为40,100美元。
(1)肾脏病治疗实践的差异导致活体供肾肾移植率相差2.5至4.0倍,表明主治肾病专家对患者的教育会影响活体供肾移植率;(2)通过此类教育,活体供肾与尸体供肾的联合器官供应几乎可满足移植需求;(3)与透析相比,活体供肾肾移植能带来更好的生活质量和成本控制,其年度费用仅为透析的四分之一。